once-daily replacement for the treatment of Addison disease, costing £43 per annum in the United Kingdom compared with £2,900 for MR-hydrocortisone. To date, randomized controlled trials comparing outcomes from different glucocorticoid replacement regimens in patients with adrenal failure have only been carried out with MR-hydrocortisone. The utility of cheaper drugs like prednisolone is unknown because of a reluctance to conduct expensive randomized controlled trials to test them.
For patients with Addison disease, the dose of glucocorticoid and the timing of treatment are crucial for achieving a satisfactory quality of life. If a patient does not receive a high enough dose of glucocorticoid at the right time, they are at increased risk of morbidity and mortality resulting from an Addisonian crisis. In the past, most clinicians have erred on the side of excess replacement to avoid such a crisis [3] [4] [5] but the association of high doses of glucocorticoid with cardiovascular mortality is concerning.
identical to that of MR-hydrocortisone. We now need a randomized controlled trial to compare once-daily prednisolone with oncedaily MR-hydrocortisone and thrice-daily hydrocortisone to determine which of the three has the best outcomes.
We believe that prednisolone, when used at the correct dose, might be the perfect replacement therapy in view of its very low cost, wide-spread availability and perfect plasma profile when taken once daily 7 . There is evidence that it is at least not inferior to the currently most widely used therapy, thrice-daily hydrocortisone 2 .
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